ipd

Medtech Companies Gained 45.6% in FY15, And A Strong FY16 Expected

Canaccord Genuity
Canaccord Genuity
Stockbroker

Impedimed: Getting Significant Recognition In The Medical Community

Canaccord Genuity
Canaccord Genuity
Stockbroker

3 short-term Biotech plays

Livewire Equities
Livewire Equities
Livewire

Lack of news flow has created an opportunity in IPD which has FDA approval and a full US Medicare reimbursement code that goes live on 01 January 2015 for its...

Canaccord Genuity
Canaccord Genuity
Stockbroker

@morgans rate Impedimed (IPD, Outperform, Price Target A$0.30)

Livewire Equities
Livewire Equities
Livewire

@morgans have an outperform rating on Impedimed (IPD) note from Scott Power follows

Livewire Equities
Livewire Equities
Livewire